Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital

Dalbavancin is a second-generation lipoglycopeptide antibiotic with activity against Gram-positive organisms. Dalbavancin is Food and Drug Administration (FDA)-approved for acute bacterial skin and soft tissue infections (ABSSTIs). There is a lack of substantial data on dalbavancin in more invasive...

Descripción completa

Detalles Bibliográficos
Autores principales: Lueking, Richard, Wei, Wenjing, Mang, Norman S., Ortwine, Jessica K., Meisner, Jessica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927367/
https://www.ncbi.nlm.nih.gov/pubmed/36537818
http://dx.doi.org/10.1128/spectrum.02385-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927367/
https://www.ncbi.nlm.nih.gov/pubmed/36537818
http://dx.doi.org/10.1128/spectrum.02385-22

Ejemplares similares